{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:48:20Z","timestamp":1791996500646,"version":"4.4.0"},"reference-count":75,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Advances in the diagnosis and treatment of multiple myeloma have come at a rapid pace, especially with several new drugs entering the market in the last few years. However, access to and affordability of new treatments poses a major challenge, both in the United States and around the world. High costs of life-saving drugs are detrimental to both the personal finances of the individual patient, as well as society which must bear the increasing costs in terms of increased health insurance premiums, taxes, or both. The challenges are not unique to myeloma, but are commonly encountered in several other cancers as well. But to some extent these pharmacoeconomic concerns are amplified in myeloma due to the need for multidrug regimens that combine 2 or more expensive new drugs, continuous therapy, and the prolonged disease course in most patients. We examine current myeloma therapy from a pharmacoeconomic perspective, and discuss the costs involved. We outline the underlying reasons why cancer drugs are so expensive, the measures that are required to lower cost, and propose potential ways in which costs can be reduced while still delivering high-quality care.<\/jats:p>","DOI":"10.1182\/blood-2016-09-692947","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T22:49:41Z","timestamp":1476485381000},"page":"2757-2764","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":69,"title":["Next-generation multiple myeloma treatment: a pharmacoeconomic perspective"],"prefix":"10.1182","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Luc","family":"Harousseau","sequence":"additional","affiliation":[{"name":"Division of Hematology, Groupe Confluent, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2019111903243646500_B1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111903243646500_B2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajh.24236","article-title":"Myeloma today: disease definitions and treatment advances","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"issue":"8","key":"2019111903243646500_B3","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.mayocp.2015.06.001","article-title":"In support of a patient-driven initiative and petition to lower the high price of cancer drugs","volume":"90","author":"Tefferi","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"2019111903243646500_B4","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/S2352-3026(16)30074-6","article-title":"Costs of haematological disease high and rising","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"issue":"20","key":"2019111903243646500_B5","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"issue":"20","key":"2019111903243646500_B6","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2014-11-568923","article-title":"Treatment options for relapsed and refractory multiple myeloma","volume":"125","author":"Nooka","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2019111903243646500_B7","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/bmt.2015.83","article-title":"Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"30","key":"2019111903243646500_B8","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111903243646500_B9","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"17","key":"2019111903243646500_B10","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1016\/j.ejca.2006.07.009","article-title":"Inequalities in oncology care: economic consequences of high cost drugs","volume":"42","author":"Niezen","year":"2006","journal-title":"Eur J Cancer"},{"issue":"5","key":"2019111903243646500_B11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S1470-2045(15)70135-X","article-title":"NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib","volume":"16","author":"Burke","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"2019111903243646500_B12","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.mayocp.2016.04.028","article-title":"The UK cancer drugs fund experiment and the US cancer drug cost problem: bearing the cost of cancer drugs until it is unbearable","volume":"91","author":"Prasad","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"2019111903243646500_B13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"key":"2019111903243646500_B14","article-title":"Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone induction followed by lenalidomide and dexamethasone maintenance in patients with newly diagnosed myeloma without intent for immediate autologous stem cell transplant: results of the randomised phase III SWOG Trial S0777","author":"Durie","year":"","journal-title":"Lancet"},{"key":"2019111903243646500_B15","author":"Attal"},{"issue":"19","key":"2019111903243646500_B16","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111903243646500_B17","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"suppl","key":"2019111903243646500_B18","article-title":"Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): a meta-analysis (MA) of overall survival (OS) [abstract]","volume":"34","author":"Attal","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111903243646500_B19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111903243646500_B20","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111903243646500_B21","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"2019111903243646500_B22","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111903243646500_B23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111903243646500_B24","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111903243646500_B25","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111903243646500_B26","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1038\/bcj.2016.53","article-title":"New investigational drugs with single-agent activity in multiple myeloma","volume":"6","author":"Rajan","year":"2016","journal-title":"Blood Cancer J"},{"issue":"9","key":"2019111903243646500_B27","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131.421k30_3131_3136","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111903243646500_B28","first-page":"685a","article-title":"Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM). Preliminary results of a prospective randomized trial (CIAM) protocol","volume":"88","author":"Facon","year":"1996","journal-title":"Blood"},{"issue":"6","key":"2019111903243646500_B29","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321 [published correction appears in J Clin Oncol. 2006;24(17):2687]","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111903243646500_B30","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111903243646500_B31","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"2019111903243646500_B32"},{"issue":"5","key":"2019111903243646500_B33","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"key":"2019111903243646500_B34","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume-title":"Haematologica","author":"Zamagni","year":"2007"},{"issue":"6","key":"2019111903243646500_B35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","article-title":"Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111903243646500_B36","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","article-title":"Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"2019111903243646500_B37","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J"},{"issue":"3","key":"2019111903243646500_B38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"40","key":"2019111903243646500_B39","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1038\/sj.onc.1204641","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"Bergsagel","year":"2001","journal-title":"Oncogene"},{"issue":"4","key":"2019111903243646500_B40","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"9","key":"2019111903243646500_B41","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1470-2045(03)01195-1","article-title":"New insights into the pathophysiology of multiple myeloma","volume":"4","author":"Seidl","year":"2003","journal-title":"Lancet Oncol"},{"issue":"26","key":"2019111903243646500_B42","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111903243646500_B43","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"2019111903243646500_B44","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2967\/jnumed.113.127886","article-title":"The Medical Imaging & Technology Alliance conference on research endpoints appropriate for Medicare coverage of new PET radiopharmaceuticals","volume":"54","author":"Hillman","year":"2013","journal-title":"J Nucl Med"},{"issue":"10040","key":"2019111903243646500_B45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(16)30954-0","article-title":"Multiple myeloma--translation of trial results into reality","volume":"388","author":"Moreau","year":"2016","journal-title":"Lancet"},{"key":"2019111903243646500_B46","author":"Roy"},{"issue":"1","key":"2019111903243646500_B47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2019111903243646500_B48","doi-asserted-by":"crossref","first-page":"f5147","DOI":"10.1136\/bmj.f5147","article-title":"Study finds that half of Indian households affected by cancer have to sell assets to fund care","volume":"347","author":"Datta","year":"2013","journal-title":"BMJ"},{"key":"2019111903243646500_B49","unstructured":"Rajkumar\n              SV\n            \n          . The ENDEAVOR Trial: a case study in the interpretation of modern cancer trials. The ASCO Post. 10 June 2016. Available at: http:\/\/www.ascopost.com\/issues\/june-10-2016\/the-endeavor-trial-a-case-study-in-the-interpretation-of-modern-cancer-trials\/. Accessed 9 September 2016."},{"issue":"19","key":"2019111903243646500_B50","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJMp1512750","article-title":"New math on drug cost-effectiveness","volume":"373","author":"Bach","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111903243646500_B51","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.mayocp.2012.07.007","article-title":"The high cost of cancer drugs and what we can do about it","volume":"87","author":"Siddiqui","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2019111903243646500_B52","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.mayocp.2015.01.014","article-title":"Why are cancer drugs so expensive in the United States, and what are the solutions?","volume":"90","author":"Kantarjian","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"23","key":"2019111903243646500_B53","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1001\/jama.2015.16843","article-title":"Payer and policy maker steps to support value-based pricing for drugs","volume":"314","author":"Bach","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"2019111903243646500_B54","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1200\/JCO.2006.09.0803","article-title":"Economics of new oncology drug development","volume":"25","author":"DiMasi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111903243646500_B55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/jama.2016.5998","article-title":"Implications of proposed Medicare reforms to counteract high cancer drug prices","volume":"316","author":"Mailankody","year":"2016","journal-title":"JAMA"},{"issue":"suppl 1","key":"2019111903243646500_B56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1634\/theoncologist.2010-S1-13","article-title":"The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology","volume":"15","author":"McKee","year":"2010","journal-title":"Oncologist"},{"issue":"9900","key":"2019111903243646500_B57","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(13)61724-9","article-title":"Health technology assessment in the UK","volume":"382","author":"Raftery","year":"2013","journal-title":"Lancet"},{"key":"2019111903243646500_B58","article-title":"The value of medicines: a crucial but vague concept [published online ahead of print 21 July 2016]","author":"Anto\u00f1anzas","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2019111903243646500_B59","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"issue":"9","key":"2019111903243646500_B60","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1200\/JCO.2015.63.7397","article-title":"Walking the tightrope between treatment efficacy and price","volume":"34","author":"Bach","year":"2016","journal-title":"J Clin Oncol"},{"key":"2019111903243646500_B61"},{"issue":"5","key":"2019111903243646500_B62","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1377\/hlthaff.2014.0552","article-title":"Comparative effectiveness and cost-effectiveness analyses frequently agree on value","volume":"34","author":"Glick","year":"2015","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"2019111903243646500_B63","first-page":"9","article-title":"The Institute for Clinical and Economic Review and its growing influence on the US healthcare","volume":"9","author":"Pizzi","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"2019111903243646500_B64","article-title":"Financial relationships with industry among National Comprehensive Cancer Network guideline authors [published online ahead of print 25 August 2016]","author":"Mitchell","journal-title":"JAMA Oncol"},{"key":"2019111903243646500_B65","unstructured":"Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Washington, DC: US Congress; 2003. Available at: https:\/\/www.congress.gov\/bill\/108th-congress\/house-bill\/1\/text. Accessed 9 September 2016."},{"key":"2019111903243646500_B66","unstructured":"Pierce\n              O\n            \n          . Medicare drug planners now lobbyists, with billions at stake. Propublica. 20 October 2009. Available at: https:\/\/www.propublica.org\/article\/medicare-drug-planners-now-lobbyists-with-billions-at-stake-1020. Accessed 9 September 2016."},{"issue":"5","key":"2019111903243646500_B67","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1377\/hlthaff.2015.1145","article-title":"Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure","volume":"35","author":"Bennette","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"2019111903243646500_B68","unstructured":"Pollack\n              A\n            \n          . Drug goes from $13.50 a tablet to $750, overnight. New York Times. 20 September 2015. Available at: http:\/\/www.nytimes.com\/2015\/09\/21\/business\/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html. Accessed 9 September 2016."},{"key":"2019111903243646500_B69","unstructured":"Parker-Pope\n              T\n            , PeachmanRR. EpiPen price rise sparks concern for allergy sufferers. New York Times. 22 August 2016. Available at: http:\/\/well.blogs.nytimes.com\/2016\/08\/22\/epipen-price-rise-sparks-concern-for-allergy-sufferers\/. Accessed 9 September 2016."},{"key":"2019111903243646500_B70","article-title":"Feasibility and attractiveness of indication value-based pricing in key EU countries","volume":"4","author":"Flume","year":"2016","journal-title":"J Mark Access Health Policy"},{"issue":"11","key":"2019111903243646500_B71","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1182\/blood-2015-11-680058","article-title":"Strategies that delay or prevent the timely availability of affordable generic drugs in the United States","volume":"127","author":"Jones","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019111903243646500_B72","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10198-013-0556-2","article-title":"Compulsory licensing and access to drugs","volume":"16","author":"Stavropoulou","year":"2015","journal-title":"Eur J Health Econ"},{"key":"2019111903243646500_B73","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijcard.2015.02.112","article-title":"Adaptive licensing - a way forward in the approval process of new therapeutic agents in Europe","volume":"184","author":"Rosano","year":"2015","journal-title":"Int J Cardiol"},{"issue":"5","key":"2019111903243646500_B74","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.molonc.2014.10.009","article-title":"Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development","volume":"9","author":"J\u00f6nsson","year":"2015","journal-title":"Mol Oncol"},{"issue":"14","key":"2019111903243646500_B75","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJMe1609835","article-title":"Progress in myeloma - a monoclonal breakthrough","volume":"375","author":"Rajkumar","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/24\/2757\/1357961\/blood692947.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/24\/2757\/1357961\/blood692947.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:25:11Z","timestamp":1574133911000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/24\/2757\/35960\/Nextgeneration-multiple-myeloma-treatment-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,15]]},"references-count":75,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2016,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-09-692947","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,15]]}}}